Approved for use through 07/31/2012: OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

STATEMENT UNDER 37 CFR 3.73(b)
Applicant/Patent Owner: Yutaka Nomura et al.
Application No./Patent No.: 6,387,908 Filed/Issue Date: May 14, 2002
EPOXYSUCCINAMIDE DERIVATIVES
Velcura Therapeutics, Inc. , a Corporation
(Name of Assignee) (Type of Assignee, e.g., comporation, partnership, university, government agency, etc.
states that it is:
the assignee of the entire right, title, and interest in;
2. an assignee of less than the entire right, title, and interest in (The extent (by percentage) of its ownership interest is%); or
3. the assignee of an undivided interest in the entirety of (a complete assignment from one of the joint inventors was made)
the patent application/patent identified above, by virtue of either:
A. X An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel, Frame, or for which a copy therefore is attached.
OR .
B. A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as follows:
1. From: To:
The document was recorded in the United States Patent and Trademark Office at
Reel, Frame, or for which a copy thereof is attached.
2. From: To:
The document was recorded in the United States Patent and Trademark Office at
Reel, Frame, or for which a copy thereof is attached.
3. From: To:
The document was recorded in the United States Patent and Trademark Office at
Reel, Frame, or for which a copy thereof is attached.
Additional documents in the chain of title are listed on a supplemental sheet(s).
As required by 37 CFR 3.73(b)(1)(i), the documentary evidence of the chain of title from the original owner to the assignee was or concurrently is being, submitted for recordation pursuant to 37 CFR 3.11.
[NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, to record the assignment in the records of the USPTO. See MPEP 302.08]
The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.
Signature
Michael W. Long President and CEO
Printed or Typed Name Title

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentially is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandra, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



United States Patent and Trademark Office





Electronic Patent Assignment System

Confirmation Receipt

Your assignment has been received by the USPTO. The coversheet of the assignment is displayed below:

PATENT ASSIGNMENT

Electronic Version v1.1 Stylesheet Version v1.1

SUBMISSION TYPE:

NEW ASSIGNMENT

NATURE OF CONVEYANCE:

ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
Nippon Chemiphar Co., Ltd.	10/05/2011

RECEIVING PARTY DATA

Name:	Velcura Therapeutics, Inc.
Street Address:	570 High St.
City:	Northville
State/Country:	MICHIGAN
Postal Code:	48167

PROPERTY NUMBERS Total: 2

Property Type	Number	
Patent Number:	6387908	
Patent Number:	6689785	

USPTO. EPAS. Receipt Page 2 of 2

CORRESPONDENCE DATA

 Fax Number:
 (269)337-7701

 Phone:
 734-418-4264

 Email:
 patents@honigman.com

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent via US Mail.

Correspondent Name: Fernando Alberdi, Ph.D.
Address Line 1: 350 East Michigan Avenue

Address Line 2: Suite 300

Address Line 4: Kalamazoo, MICHIGAN 49007-3800

ATTORNEY DOCKET

NUMBER:

219977-313728/313729

NAME OF SUBMITTER: Fernando Alberdi, Ph.D.

Signature: /Fernando Alberdi, Ph.D./

Date: 11/14/2011

Total Attachments: 3

source=2011-11-11 (219977-313728) Assignment Fully Executed#page1.tif source=2011-11-11 (219977-313728) Assignment Fully Executed#page2.tif source=2011-11-11 (219977-313728) Assignment Fully Executed#page3.tif

RECEIPT INFORMATION

EPAS ID: PAT1754116
Receipt Date: 11/14/2011
Fee Amount: \$80

Return to home page Start another assignment from the same template

| HOME | INDEX | SEARCH | eBUSINESS | CONTACT US | PRIVACY STATEMENT

ASSIGNMENT

We, Nippon Chemiphar Co., Ltd., a Japanese Company, having an office and a place of business at 2-2-3, Iwamoto-cho, Chiyoda-ku, Tokyo 101-0032, Japan, for good and valuable consideration, receipt of which is hereby acknowledged, have assigned, sold and transferred to, and do hereby assign, sell and transfer to, Velcura Therapeutics, Inc., a corporation organized and existing under the laws of Delaware, and having an office and a place of business at 570 High St. Northville, Michigan 48167, U.S.A., its successors and assigns, all hereinafter referred to as the ASSIGNEE:

(1) the entire right, title and interest, in the following patents:

Title: Epoxysuccinamide Derivatives

Patent No.	Country	Filing Date
1022276	Europe	9/4/1998
241607	Austria	9/4/1998
1022276	Belgium	9/4/1998
1022276	Denmark	9/4/1998
1022276	Finland	9/4/1998
1022276	France	9/4/1998
69815137	Germany	9/4/1998
1022276	Great Britain	9/4/1998
1022276	Greece	9/4/1998
1022276	Ireland	9/4/1998
1022276	Italy	9/4/1998
1022276	Luxembourg	9/4/1998
1022276	Monaco	9/4/1998
1022276	Netherlands	9/4/1998
1022276	Portugal	9/4/1998
2201524	Spain	9/4/1998
1022276	Sweden	9/4/1998
1022276	Switzerland	9/4/1998
4336039	Japan	9/4/1998
6387908	United States	9/4/1998
6689785	United States	9/4/1998

- (2) the full and complete right to file patent applications in the name of the ASSIGNEE, its designee, or in my/our names at the election of the ASSIGNEE or its designee, on the aforesaid inventions, discoveries and applications in any country throughout of the world;
- (3) the entire right, title and interest in and to any Letters Patent which may issue thereon in any country throughout the world, and in and to any renewals, revivals, reissues, reexaminations, extensions, continuations and divisions thereof; and

Title: Epoxysuccinamide Derivatives

(4) the entire right, title and interest in and to all Convention and Treaty Rights of all kinds thereon, including without limitation all rights of priority in any country of the world, in and to the above inventions, discoveries and applications.

We hereby authorize and request the competent authorities to grant and to issue any and all such Letters Patent throughout the world to the ASSIGNEE of the entire right, title and interest therein, as fully and entirely as the same would have been held and enjoyed by me/us had this assignment, sale and transfer not been made.

By: Kozushiro	
Kazushiro Yamag	gukhi 0
President and CE	O of
Nippon Chemipha	ar Co., Ltd

Date: Oct. 5, 2011

Witnessed by:
Signature
Date:
Printed Name:
Address:

Witnessed by:
Signature
Date:
Printed Name:
Date:
Printed Name:
Address:

Masao Yamamoto
Tokyo, Japan

K.Y

ACKNOWLEDGMENT OF ASSIGNEE

By: Nichael W. Sey	
Michael W. Long	
President and CEO	
Velcura Therapeutics, Inc.	
Date:	
State of Michigan County of WISHTENNY	

Notary Public

My Commission Expires

LINDA A. ZERSY

NOTARY PUBLIC, STATE OF MI

COUNTY OF WAYNE

MY COMMISSION EXPIRES JUL 1, 201 \$

ACTING IN COUNTY OF

KJ